Skip to main content

Mark A. Socinski, MD

Mark A. Socinski , MD

Executive Medical Director of the AdventHealth Cancer Institute, Medical Oncologist

Cancer

Mark A. Socinski

Overview

Dr. Mark A. Socinski is a board-certified, fellowship trained medical oncologist, specializing in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. He is an internationally recognized expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. His research has focused on incorporating personalized medicine and molecular biomarkers in the treatment of lung cancer. Dr. Socinski formerly served as Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. He also serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative clinical trials. He is the Executive Medical Director of the AdventHealth Cancer Institute.

Articles

A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials

BMC CANCER

2024

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

NATURE MEDICINE

2023

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

CLINICAL CANCER RESEARCH

2023

Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials

The oncologist

2023

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials

JAMA ONCOLOGY

2023

Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine

FRONTIERS IN ONCOLOGY

2023

A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2

ECLINICALMEDICINE

2023

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer

CLINICAL CANCER RESEARCH

2023

Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

Clinical lung cancer

2023

Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (AvastinĀ®) in Patients with Non-squamous Non-small Cell Lung Cancer

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

2023

Education & Training

Education

University of Vermont, Burlington, VT

Residency

Harvard Medical School/Beth Israel Hospital, Boston

Fellowship

Harvard Medical School/Beth Israel Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA

Specialty

Medical Oncology

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT04746924

A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

Icon for trial | BGB-A317-A1217-302 A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Met

This study will look at the efficacy and safety of combined treatment with 2 anticancer drugs, which are called tislelizumab (also known as BGB-A317) and BGB-A1217 compared to treatment with pembrolizumab and saline (a mix of s ...